Your browser doesn't support javascript.
loading
Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome.
Yeter, Hasan H; Derici, Ulver; Arinsoy, Turgay; Altok, Kadriye; Erten, Yasemin; Guz, Galip.
Afiliación
  • Yeter HH; Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Derici U; Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Arinsoy T; Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Altok K; Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Erten Y; Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Guz G; Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey.
Rom J Intern Med ; 60(1): 56-65, 2022 Mar 01.
Article en En | MEDLINE | ID: mdl-34449174
Introduction. The aim was to evaluate the effect of therapeutic plasma exchange (TPE) and eculizumab on hematological and renal survival in atypical hemolytic uremic syndrome (aHUS), and additionally, to examine the reliability of discontinuation of eculizumab treatment.Methods. This was an observational and retrospective study of 18 patients diagnosed with aHUS.Results. The median age of the study population was 30 (22-66) years. Four of 18 patients achieved hematological remission with the TPE alone. However, one patient died after three sessions of TPE. Eculizumab was used in 13 patients and no death was observed. One year after treatment, improved kidney function was observed in 2 of 3 (66%) patients for TPE and 5 of 9 (56%) patients for Eculizumab. We discontinued eculizumab treatment in 9 patients. One of the patients who had a C3 gene mutation experienced disease relapse after Eculizumab discontinuation. None of the patients who had drug associated aHUS developed disease relapse after Eculizumab discontinuation.Conclusion. Eculizumab treatment is a life-saving therapy in aHUS. Treatment discontinuation may be considered at least six months after hematologic remission in patients who had stable renal function or no expectancy for renal survival. Moreover, drug-associated cases seem to tend not to develop disease relapse in the long term.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Síndrome Hemolítico Urémico Atípico Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Humans / Middle aged Idioma: En Revista: Rom J Intern Med Asunto de la revista: MEDICINA INTERNA Año: 2022 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Síndrome Hemolítico Urémico Atípico Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Humans / Middle aged Idioma: En Revista: Rom J Intern Med Asunto de la revista: MEDICINA INTERNA Año: 2022 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Alemania